The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Solid tumors, mRNA, and two of the COVID vaccines

Tamlen
Tamlen CSN Member Posts: 343 Member
in Uterine/Endometrial Cancer #1

Reuters published this today:

mRNA Vaccines May Need More Study for Treating Some Cancer Patients

COVID-19 vaccines that employ new messenger RNA (mRNA) technology to fend off the illness may require further testing before it becomes clear they are safe for cancer patients with solid tumors, cancer treatment experts say. That would include the vaccines from Pfizer Inc with partner BioNTech SE and from Moderna Inc. The vaccines work by carrying genetic instructions for making a protein from the virus that the immune system learns to recognize and defend against. The mRNA is encased in a microscopic "packet" called a lipid nanoparticle (LNP), or liposome, that protects and delivers the fragile molecule into cells. While this technique is new for vaccines, it has long been used to carry cancer drugs into tumors, because tumors easily take up liposomes. This raises the possibility that tumor tissues would capture some of the liposomes carrying the vaccine's mRNA, said Gerard Milano of Nice University in France. The potential for part of the vaccine to become stuck in tumors and the resulting effect on cancer patients "is an open question to which there is currently no answer," Milano said. In a paper published on Wednesday in the British Journal of Cancer, his team calls for "a careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumors, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population." (go.nature.com/2JQq4hV)

Like Care

Comments

Discussion Boards